公司

Retension Pharmaceuticals, Inc.

关注打开结构图就此提问研究这家公司

简介

总部: US

Retension Pharmaceuticals, Inc. 的结构

Retension Pharmaceuticals, Inc.

公司

4 个关联

上游供应与依赖

关系出现时间2026

Retension Pharmaceuticals, Inc.公司 · 4 个关联

第 1 层

上游供应与依赖4

关系

箭头表示关系方向，可按业务类别筛选。

Leerink Partners服务于 →Retension Pharmaceuticals, Inc.
公司 · Leerink Partners证据 1
事实90%
查看证据
- 公司披露GlobeNewswire public company news2026-10-09 09:35
  Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering.
  查看来源
Guggenheim Securities服务于 →Retension Pharmaceuticals, Inc.
公司 · Guggenheim Securities证据 1
事实90%
查看证据
- 公司披露GlobeNewswire public company news2026-10-09 09:35
  Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering.
  查看来源
Oppenheimer & Co.服务于 →Retension Pharmaceuticals, Inc.
公司 · Oppenheimer & Co.证据 1
事实90%
查看证据
- 公司披露GlobeNewswire public company news2026-10-09 09:35
  Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering.
  查看来源
Titan Partners服务于 →Retension Pharmaceuticals, Inc.
公司 · Titan Partners证据 1
事实90%
查看证据
- 公司披露GlobeNewswire public company news2026-10-09 09:35
  Titan Partners is acting as lead manager for the offering.
  查看来源

显示第 1 至 4 条，共 4 条

结论

结合来源阅读结论，展开条目查看证据。

事实证据 1

initial public offering shares3,750,000 shares

pricing of its upsized initial public offering of 3,750,000 shares of its common stock

GlobeNewswire public company news · 2026-10-09 09:35

查看证据

公司披露GlobeNewswire public company news2026-10-09 09:35
pricing of its upsized initial public offering of 3,750,000 shares of its common stock
查看来源

事实证据 1

initial public offering price$12.00 per share

at an initial public offering price of $12.00 per share

GlobeNewswire public company news · 2026-10-09 09:35

查看证据

公司披露GlobeNewswire public company news2026-10-09 09:35
at an initial public offering price of $12.00 per share
查看来源

事实证据 1

expected gross proceeds$45.0 million

The gross proceeds to Retension from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Retension, are expected to be $45.0 million.

GlobeNewswire public company news · 2026-10-09 09:35

查看证据

公司披露GlobeNewswire public company news2026-10-09 09:35
The gross proceeds to Retension from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Retension, are expected to be $45.0 million.
查看来源

事实证据 1

underwriters option term30-day

Retension has granted the underwriters a 30-day option

GlobeNewswire public company news · 2026-10-09 09:35

查看证据

公司披露GlobeNewswire public company news2026-10-09 09:35
Retension has granted the underwriters a 30-day option
查看来源

事实证据 1

additional shares available under underwriters option562,500 shares

option to purchase up to an additional 562,500 shares of its common stock

GlobeNewswire public company news · 2026-10-09 09:35

查看证据

公司披露GlobeNewswire public company news2026-10-09 09:35
option to purchase up to an additional 562,500 shares of its common stock
查看来源

事实证据 1

服务于Leerink Partners

Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering.

GlobeNewswire public company news · 2026-10-09 09:35

查看证据

公司披露GlobeNewswire public company news2026-10-09 09:35
Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering.
查看来源

显示第 1 至 6 条，共 9 条

市场与估值

估值数据需要 Pro 或 Research。

升级到 Pro 解锁

暂无: 公司信号 · 财务数据 · 披露文件 · 业绩指引